Company Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| Founded | 1979 |
| IPO Date | May 18, 1992 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 48,000 |
| CEO | Michael F. Mahoney |
Contact Details
Address: 300 Boston Scientific Way Marlborough, Massachusetts 01752-1234 United States | |
| Phone | 508-683-4000 |
| Website | bostonscientific.com |
Stock Details
| Ticker Symbol | BSX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885725 |
| CUSIP Number | 101137107 |
| ISIN Number | US1011371077 |
| Employer ID | 04-2695240 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael F. Mahoney | Chairman, President and Chief Executive Officer |
| Daniel J. Brennan | Executive Vice President and Chief Financial Officer |
| Joseph M. Fitzgerald | Executive Vice President and Group President of Cardiology |
| Jeffrey B. Mirviss | Executive Vice President and President of Peripheral Interventions |
| Arthur Crosswell Butcher | Executive Vice President and Group President of MedSurg and Asia Pacific |
| David J. Roux | Independent Director |
| John Bradley Sorenson | Executive Vice President of Global Operations |
| Emily Woodworth | Senior Vice President, Global Controller and Chief Accounting Officer |
| Jodi Euerle Eddy | Senior Vice President and Chief Information and Digital Officer |
| Jonathan R Monson | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | ARS | Filing |
| Mar 18, 2024 | 144 | Filing |
| Mar 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 1, 2024 | 144 | Filing |